Barclays’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-1,000
| Closed | -$63K | – | 6409 |
|
|
2020
Q1 | $63K | Sell |
1,000
-100
| -9% | -$8.99K | ﹤0.01% | 5091 |
|
|
2019
Q4 | $136K | Sell |
1,100
-1,200
| -52% | -$107K | ﹤0.01% | 5294 |
|
|
2019
Q3 | $153K | Buy |
2,300
+1,200
| +109% | +$80.6K | ﹤0.01% | 5156 |
|
|
2019
Q2 | $88K | Sell |
1,100
-202,700
| -99% | -$18.1M | ﹤0.01% | 5782 |
|
|
2019
Q1 | $22.8M | Buy |
203,800
+163,500
| +406% | +$17.9M | 0.02% | 774 |
|
|
2018
Q4 | $4.06M | Buy |
40,300
+200
| +0.5% | +$20.7K | ﹤0.01% | 1740 |
|
|
2018
Q3 | $5.07M | Buy |
40,100
+100
| +0.3% | +$10.6K | ﹤0.01% | 1805 |
|
|
2018
Q2 | $3.36M | Buy |
+40,000
| New | +$2.93M | ﹤0.01% | 2074 |
|
|
2018
Q1 | – | Sell |
-25,100
| Closed | -$1.47M | – | 7421 |
|
|
2017
Q4 | $1.47M | Hold |
25,100
| – | – | ﹤0.01% | 2742 |
|
|
2017
Q3 | $1.46M | Buy |
25,100
+24,000
| +2,182% | +$2.59M | ﹤0.01% | 2648 |
|
|
2017
Q2 | $133K | Sell |
1,100
-83,900
| -99% | -$9.72M | ﹤0.01% | 4708 |
|
|
2017
Q1 | $9.61M | Buy |
85,000
+49,500
| +139% | +$5.78M | 0.01% | 899 |
|
|
2016
Q4 | $3.86M | Buy |
35,500
+27,300
| +333% | +$3.25M | ﹤0.01% | 1569 |
|
|
2016
Q3 | $1.35M | Sell |
8,200
-10,000
| -55% | -$1.58M | ﹤0.01% | 2346 |
|
|
2016
Q2 | $2.6M | Sell |
18,200
-3,000
| -14% | -$437K | ﹤0.01% | 1805 |
|
|
2016
Q1 | $2.71M | Buy |
+21,200
| New | +$2.5M | ﹤0.01% | 1666 |
|
|
2015
Q1 | – | Sell |
-18,400
| Closed | -$2.87M | – | 7309 |
|
|
2014
Q4 | $2.87M | Sell |
18,400
-12,000
| -39% | -$2.22M | ﹤0.01% | 2202 |
|
|
2014
Q3 | $7.17M | Sell |
30,400
-14,600
| -32% | -$3.72M | 0.01% | 1448 |
|
|
2014
Q2 | $10.6M | Sell |
45,000
-4,200
| -9% | -$1.11M | 0.01% | 1110 |
|
|
2014
Q1 | $16.2M | Buy |
+49,200
| New | +$16.6M | 0.02% | 825 |
|
Barclays's ICPT Position: Q4 2023 in Review
Barclays sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 178,438 shares — an estimated $3.31M sold.
Barclays first reported a position in ICPT in Q2 2013 and held it in 42 quarters. The position peaked at $15.7M in Q1 2020. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Barclays reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Barclays sold 178,438 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $3.31M.
- Barclays first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 42 quarters.
- Barclays's Intercept Pharmaceuticals, Inc. position peaked at $15.7M in Q1 2020.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Barclays's 13F filing for Q4 2023, filed 15 Feb 2024.